{
    "2020-03-02": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Top Stock Reports for Eli Lilly, Union Pacific & Lockheed",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Union Pacific",
                        "Lockheed"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "transportation",
                        "defense"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "This is Why Eli Lilly (LLY) is a Great Dividend Stock",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Dividend",
                        "Stock"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-22",
                "original_text": "U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis",
                "features": {
                    "keywords": [
                        "FDA",
                        "Tanezumab",
                        "First-in-Class",
                        "Chronic Pain",
                        "Osteoarthritis"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}